Recruiting
Albuminuria Reduction Trial and Investigation with Survodutide Treatment in CKD (ARTIST-CKD)
2025-525068-13-00· Phase 2· Universitair Medisch Centrum Groningen· Source
Active, not recruiting
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.
2023-503298-39-00· Phase 3· AstraZeneca AB· Source
Not yet recruiting
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
NCT07486687· Phase 3· The Netherlands Cancer Institute· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· Phase 3· Incyte Corporation· Source
Not yet recruiting
Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer Using Durvalumab-680LT and Nivolumab-800CW
NCT07196384· Phase 1· University Medical Center Groningen· Source
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Recruiting
Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation
NCT07267949· Phase 2· Acesion Pharma· Source
Recruiting
ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer
NCT07188025· Phase 3· Erasmus Medical Center· Source
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
2022-502352-31-00· Phase 3· Amgen Inc.· Source
Recruiting
The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial
2024-514055-15-00· Phase 4· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source
Recruiting
Can we Save the rectum by watchful waiting or transanal surgery following short- or long-course radioTherapy and Additional local oR systemic Treatment for early-stage REctal Cancer?
2024-514620-17-00· Phase 2· Radboud universitair medisch centrum Stichting· Source
Active, not recruiting
Dose tapering and Early Discontinuation to InCreAse cosT-effictIveness Of immunotherapy for Non-small cell lung carcinoma trial number 1 (NVALT-30 - Dedication-1)
NCT04909684· Phase 3· Stichting Radboud universitair medisch centrum· Source
Recruiting
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
NCT06220032· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Active, not recruiting
DUTCH Weight Control in Atrial Fibrillation Study
NCT06184633· Phase 4· Rijnstate Hospital· Source
Recruiting
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
NCT06187441· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821· Phase 3· BeOne Medicines· Source
Active, not recruiting
The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
NCT05374291· Phase 3· University Medical Center Groningen· Source
Recruiting
Pregnancy Outcomes: Effects of Metformin Study (POEM Study)
NCT02947503· Phase 3· Bethesda Diabetes Research Center· Source
Recruiting
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
NCT03968393· Phase 4· Population Health Research Institute· Source
Active, not recruiting
Can we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?
NCT02945566· Phase 2/3· University of Birmingham· Source
Recruiting
DRUP trial
NCT02925234· Phase 2· Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting· Source
Active, not recruiting
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
NCT01898117· Phase 2· The Netherlands Cancer Institute· Source